# Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

> **NCT01226797** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-04136309

## Key facts

- **NCT ID:** NCT01226797
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01-17
- **Primary completion:** 2012-02-09
- **Final completion:** 2012-02-09
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226797, "Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01226797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*